Will SGI affirm or raise the Mattress Firm $225M run-rate synergy target at FY2026 year-end earnings?
Current Prediction
Why This Question Matters
The $225M raised synergy target is management's credibility benchmark. Affirmation or raise at FY2026 year-end validates that Leggett execution concentration did not disrupt Mattress Firm integration. A guide-down would confirm the primary risk identified by Consolidation Calibrator — stacked deal execution. This is a year-end 2026 readthrough on whether the consolidator track record extends through the current stack.
Prediction Distribution
Individual Predictions(9 runs)
Base rate: acquisitions with synergy capture ahead of schedule in year 1 typically hold/raise the target in year 2 at ~75-85%. SGI already raised from $200M to $225M, which is evidence of conservative initial target. $80M captured in 2025 vs original $200M target on schedule; now tracking toward $225M. Management's cadence of quarterly synergy updates makes silence unlikely at FY2026 year-end earnings. Discount for stacked Leggett execution: -5pp. Discount for industry weakness affecting sales-synergy portion: -5pp. Net: 0.72.
Management track record: prior consolidator deals (Sealy 2013, Tempur Sealy 2022) saw synergy targets held or raised in subsequent years. The $225M raise is itself a commitment. Q4 2026 call (Feb 2027) is ~10 months away; by then 2/3 of the synergy journey will be complete. Strong structural reasons to affirm: (a) management incentives, (b) 2028 EPS target depends on it, (c) investor relations committed cadence. Primary downside: Leggett integration distracting or specific cost-synergy projects slipping. Probability 0.75.
Key risk underweighted: sales synergy portion ($100M run-rate, $60M delivered 2025 + $40M wraparound 2026) depends on category demand and continued balance-of-share gains. If industry deteriorates further, sales synergy could underperform. Cost synergy ($125M) is more controllable. If cost synergy is on track but sales synergy underperforms, management might affirm total target via pro-forma adjustments or might quietly revise down. Silence-as-NO criteria is strict. Land at 0.70.
Three elements support YES: (a) ahead-of-schedule capture in 2025, (b) management consistent update cadence, (c) structural incentives to affirm. Two elements against: (a) Leggett execution concentration, (b) industry cyclical risk for sales-synergy portion. Net 0.72.
Slightly more cautious: the 10-month horizon introduces path-dependency. If Q2 or Q3 2026 shows Mattress Firm L-f-L weakness, sales synergy delivery is at risk. Cost synergy remains solid. Management might affirm even with mix shift (cost synergy higher, sales lower). Probability 0.70.
Weight of evidence favors affirmation: $225M was itself raised; 2025 delivery on pace; 2028 EPS target dependency creates strong incentive to affirm. Cost synergy initiatives ($55M 2026 + $50M 2027 incremental) are largely distribution/procurement, which are execution-controllable. Land at 0.73.
Base rate ~75% for hold/raise in year 2 when year 1 delivery is ahead. Discount for Leggett distraction and industry risk. Land at 0.72.
Moderate lean YES. Management has strong reasons to affirm; primary risk is silence-at-year-end in favor of more granular guidance framework. 0.70.
Track record of raising (Sealy, Tempur Sealy precedent) plus 2025 pace on $225M target supports affirmation. Leggett risk moderate. 0.74.
Resolution Criteria
Resolves YES if SGI Q4 2026 earnings release or call (expected February 2027) explicitly affirms or raises the $225M Mattress Firm run-rate synergy target (cost + sales combined). Resolves NO if the target is explicitly reduced, or if the Q4 2026 earnings release omits a synergy target update (silence treated as de-facto reduction given management's prior cadence of explicit updates).
Resolution Source
SGI Q4 2026 earnings release, investor call transcript, or 10-K filing
Source Trigger
Mattress Firm synergy realization is running ahead of schedule — $225M raised target, $80M 2025 actual
Full multi-lens equity analysis